Summary:
Click image to enlarge
The purpose of this study is to evaluate the effectiveness and safety of an investigational compound for schizophrenia. The study consists of a 24 week outpatient study treatment period, followed by a safety follow up period. All procedures and study visits will take place at CBH Health located in Gaithersburg, MD.
• Male or Female, Ages 18-50
• Diagnosis of Schizophrenia
• Be in good physical health as ascertained by medical history, physical examination, and clinical laboratory evaluations
• History of bipolar disorder, schizoaffective disorder or Major Depressive Disorder is exclusionary.
• No seizure disorder, strokes or tumor
• Current diagnosis of substance abuse or within past 12 months is exclusionary
• Current sucidal ideation or a suicide attempt within the past 1 years is exclusionary
Qualified Participants May Receive:
Compensation will be provided.